Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 54

HOS-112191 · Präparat HOS-093615

Close monitoring of patient's virologic response should be exercised. Lamotrigine Co-administration of lamotrigine and Lamotrigine should be used REYATAZ/ritonavir may decrease with caution in combination lamotrigine plasma concentrations due to with REYATAZ/ritonavir. UGT1A4 induction. If necessary, monitor lamotrigine concentrations and adjust the dose accordingly. ANTINEOPLASTICS AND IMMUNOSUPRESSANTS Antineoplastics Apalutamide The mechanism of interaction is CYP3A4 Co-administration with induction by apalutamide and CYP3A4 REYATAZ (with or without inhibition by atazanavir/ritonavir. ritonavir) is contraindicated due to the potential for decreased atazanavir and ritonavir plasma concentration with subsequent loss of virologic response and possible resistance to the class of protease inhibitors (see section 4.3). In addition, serum concentrations of apalutamide may be increased when coadministered with atazanavir/ritonavir, resulting in the potential for serious adverse events including seizure. Encorafenib The mechanism of interaction is CYP3A4 Co-administration of inhibition by atazanavir and/or ritonavir. encorafenib with REYATAZ (with or without ritonavir) is contraindicated due to potential for loss of virologic response, development of resistance, increase in encorafenib plasma concentration and subsequent risk of serious adverse events such as QT interval prolongation (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) protease (HOS-085623) apalutamide (HOS-086212) encorafenib (HOS-086222) ritonavir (HOS-084521)